I’ve been on this board long enough to see most posters

New Post Public Reply Private Reply Replies (2) Message Board
onestepahead
576
I’ve been on this board long enough to see most posters true investment strategy. Overwhelming amount of shorts and flippers are the ones posting since last night and into this morning. There have only been a handful of longs using common sense analysis of the data and comparing it against what FDA has stated criteria for EUA and comparing against the current. For the last year we have had to deal with shorts, bashers, flippers tell us that are drug does not work on anything and that were going no where but down. They also claimed in the past that any and every competing drug was going to get approved and would be better than CYDY Leronlimab. The results that we have been given tell the real story - #1 best therapeutic at reducing mortality in the sickest (critical) patients giving them best chance of survival. There is no other drug to compare out results to unless you want to use the Latest PR comparison of 2% we are 12x better. The next data endpoint we were given was 6 days reduced hospital stay vs the SOC. Keep in mind remsavier was given EUA even though they have some pretty nasty side effects by reducing hospital stay by 2 days. Third data endpoint shows a 166% better chance compared to SOC to be discharged alive from hospital at day 28. All of these are huge breakthroughs in which no other drug can show that they could do any of those 3 things never mind the same drug replicate all those positive results. EUA is imminent we already know the FDA and CYDY would like more critical patients enrolled and I believe this path forward is aimed at full approval. FDA has a plethora of data that shows an astounding benefit vs risk (little to NO SAE) taking this drug prob would results in 99.999% chance of better recovery than getting a SAE from taking it. I hope most of the longs and even new investors understand how valuable the shares they are currently holding will be there are already a ton 20+ million short shares out and with any big media we may get over this weekend could really send this stock gapping up in multiples. If media is lagged the shorts may win at getting stock yo briefly decline but media will pick up on it and CYDY will be getting more PR out new investors and stock price will go up with communications of sales to US, MHRA, Canada, Phillipines and Brazil. Brazil might be the new front runner to take as much of the supply as they can get ans give EUA. Looking forward to Monday I think we will get more positive news.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tenant Improvement: Key to Adapting Lease Spaces

Updated Category News Views 1

Adapting Space or Adapting Business? Here's the thing that keeps popping up in commercial real estate: tenant improvement construction. This isn't just modifying a structure—it's about rethinking how businesses operate within a certain space. The HelloNation article gives you the lowdown straight from Bradley Quakenbush of White Oak Commercial Group. When businesses...

Continue Reading
Spooky Suds: House of Horror Meets El Car Wash

Updated Category News Views 0

A Haunted Wash Awaits Miami Drivers Picture this: you're cruising down West Flagler on a regular Wednesday evening, but tonight, you're not just rolling in for a rinse. Nope, this Wednesday night, the wash tunnel at El Car Wash gets downright spooky. It's getting a haunted house makeover with scare actors from the House of Horror. When a Car Wash Becomes a Haunted...

Continue Reading
LINC Lawsuit: Boardroom Stumbles Spark Investor Action

Updated Category News Views 0

Class Action Kickoff: Lincoln's Educational Curveball No one fancies home runs when the ball’s out of sight, and that’s probably how some investors in Lincoln Educational Services Corporation (NASDAQ: LINC) are feeling right now. A group of shareholders has pulled back the curtain on what they believe are more than just administrative hiccups—allegations of...

Continue Reading
Richard Huffman Joins IFA Board, Strengthens Franchise Ties

Updated Category News Views 7

Ever wonder how the cogs in this massive machine called franchising keep turning? It's folks like Richard Huffman who step up to the plate, and his recent election to the International Franchise Association (IFA) Board of Directors is worth a second glance. Huffman: A Franchise Veteran Now, Huffman isn't some rookie in the world of franchising. You see, back in '94, he...

Continue Reading
DOCS Faces Investor Legal Battle for Alleged Misconduct

Updated Category News Views 0

The DOCS Predicament: Investors Facing Class Action Doximity, Inc., trading as NYSE:DOCS, finds itself in hot water again as shareholders gear up for a legal skirmish over alleged securities fraud. Schall, Brown & Schwartz LLP, the firm rallying the shareholders, has fired the opening salvo, pointing fingers at Doximity for cooking the books about their Newsfeed’s...

Continue Reading
Navigating the Nitty-Gritty of Cabin Rental Management

Updated Category News Views 0

The Real Elbow Grease Behind Cabin Management Ever imagined what it’d take to keep a vacation rental cabin running like a tight ship? Well, Nathan Fitts breaks it down real clear-like. The guy's seen it all in Blue Ridge, Georgia, which isn't just about scenic views—there's serious business brewing behind that cabin charm. More Than Just Fluffing Pillows Turns out,...

Continue Reading
New Chapter Recovery Garners Key Accreditations

Updated Category News Views 5

Accreditations That Matter It's not every day a treatment facility pops its head up with credentials that weigh like a ton of bricks. New Chapter Recovery in New Jersey just snagged two heavy hitters: Joint Commission accreditation and LegitScript certification. These badges don’t just glimmer for show; they’re the market's assurance against empty promises—an...

Continue Reading
Plata Hits $1 Billion ARR in Record Digital Bank Growth

Updated Category News Views 0

Plata Rocks the Boat with Rapid Revenue Growth When a digital bank like Plata rakes in $1 billion in Annual Recurring Revenue (ARR) within just 3.5 years, you can't just shrug it off. That's blazing fast by any standard, especially for a financial institution. Emerging from Mexico, this bank's rocket-like ascent is flinging the doors wide open for what's possible in the...

Continue Reading
eGlint's Rapid Tech Revolutionizes Proteomics with Win

Updated Category News Views 0

A Game-Changer in Proteomics Now ain't this something—eGlint just scooped up the 2026 BioTools Innovator Grand Prize, waving a big ol' $250,000 check around and claiming the biotech spotlight with their swift-moving ProteoNex™ platform. Forget about sticking samples through sluggish labs and waiting an eternity; eGlint's tech is flipping the switch, serving up protein...

Continue Reading
Navigating AI Laws: A New Era for Privacy & Security

Updated Category News Views 1

Crucial Insights from the Convergence Conference Rich with intrigue, the privacy and AI governance game just upped its stakes. If there ever was a time to listen closely, it's now, people. With over 150 laws sprouting up faster than weeds, businesses are getting squeezed to keep their artificial ducks in a row. Last month over in New York, some big names in law and...

Continue Reading

Top 5 Most Recently Viewed Articles

David Deamer Honored with ABRF Award for Groundbreaking Work

Updated Category News Views 66

David Deamer's Remarkable Recognition Renowned scientist David Deamer, Ph.D., has been honored for his extraordinary contributions to biomolecular technologies. This distinguished recognition comes from the Association of Biomolecular Resource Facilities (ABRF), which named Deamer the recipient of their prestigious ABRF Award, an accolade given to those who have made...

Continue Reading
Qualcomm's Stock Faces Challenges Amid Apple Competition

Updated Category News Views 105

Qualcomm's Stock Performance Qualcomm Inc. (NASDAQ: QCOM) is experiencing a decline in its stock price as recent analyst evaluations raise concerns regarding its future earnings potential. This downward trend follows, in part, an important downgrade by analysts highlighting challenges ahead for the company. Understanding the Downgrade KeyBanc analyst John Vinh made...

Continue Reading
Intensity Therapeutics Achieves Nasdaq Compliance Milestone

Updated Category News Views 103

Intensity Therapeutics Regains Nasdaq Compliance Intensity Therapeutics, Inc. (NASDAQ: INTS) is excited to share significant news regarding its compliance status with Nasdaq's minimum stockholders' equity requirement. The company, committed to developing innovative intratumoral cancer therapies, recently received a notification from the Listing Qualifications Staff of The...

Continue Reading
Resmed Inc. Delivers Robust Earnings Growth in Latest Report

Updated Category News Views 147

Strong Financial Performance from Resmed Inc. Resmed Inc. (NYSE: RMD, ASX: RMD) has announced impressive financial results for its latest quarter, indicating clear growth and sustained demand for its innovative health solutions in sleep and breathing fields. The company's revenue saw an encouraging year-over-year increase of 8%, rising to $1.3 billion. Notably, this...

Continue Reading
Fangzhou Unveils Cutting-Edge Leukemia Treatment Platform

Updated Category News Views 189

Fangzhou Brings Otsuka's Ponatinib to Patients Fangzhou Inc., a leader in innovative healthcare solutions, has announced the launch of Otsuka Pharmaceutical's third-generation tyrosine kinase inhibitor. This groundbreaking treatment is known as Ponatinib, also branded as Iclusig® and is now accessible through Fangzhou's online platform. This offering significantly...

Continue Reading